All In Biotech

Drug Trial Radar · NCT04322149

Multiple Doses of AT-1501-A201 in Adults With ALS

A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS

Last checked: Nov 19, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Oct 16, 2020

Primary completion

Mar 24, 2022

Study completion Mar 24, 2022

Sponsor

Lead sponsor
Anelixis Therapeutics, LLCIndustry
Sponsor type
Industry
First posted
Mar 26, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a, multi-center, open label, multiple dose study of AT-1501, a humanized monoclonal antibody antagonist to CD40 ligand (CD40L). Approximately 54 adults with Amyotrophic Lateral Sclerosis (ALS) will be enrolled into the study in the United States and Canada at approximately 13 ALS treatment sites. Participants will be enrolled into one of four ascending doses.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • AT-1501Drug

    AT-1501 monoclonal antibody targeting CD40L given as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Up to 18 Weeks
  2. Safety and TolerabilityTime frame: Up to 18 Weeks

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Barrows Neurological Institute

    Phoenix, Arizona

  • University of California Irvine

    Orange, California

  • California Pacific Medical Center

    San Francisco, California

  • Augusta University

    Augusta, Georgia

  • University of Indiana

    Indianapolis, Indiana

  • The University of Kansas Medical Center

    Kansas City, Kansas

  • Johns Hopkins University Medical Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hospital for Special Surgery (HSS)

    New York, New York

  • Providence Brain & Spine Institute

    Portland, Oregon

  • Texas Neurology, P.A.

    Dallas, Texas

  • Houston Methodist Neurological Institute

    Houston, Texas

  • Montreal Neurological Institute and Hospital

    Montreal, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.